Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Azacitidine

Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Celgene Corporation

INDUSTRY

lead

Virginia Commonwealth University

OTHER